Biodiversity Literature Repository
Published November 18, 2014 | Version v1
Journal article Open

Challenges of drug-resistant malaria

Creators

Description

Sinha, Shweta, Medhi, Bikash, Sehgal, Rakesh (2014): Challenges of drug-resistant malaria. Parasite (Paris, France) 21: 1-15, DOI: 10.1051/parasite/2014059, URL: http://dx.doi.org/10.1051/parasite/2014059

Files

source.pdf

Files (952.8 kB)

Name Size Download all
md5:622d294bd562a72ac32252a4b7591fb3
952.8 kB Preview Download

Linked records

Additional details

Identifiers

LSID
urn:lsid:plazi.org:pub:622D294BD562A72AC322FFA4B759FFB3

Related works

Has part
Figure: 10.5281/zenodo.12524197 (DOI)
Dataset: http://table.plazi.org/id/42C2B0ADD560A728C353FB58B36EFAA2 (URL)
Figure: 10.5281/zenodo.12524199 (DOI)
Dataset: http://table.plazi.org/id/42C2B0ADD565A72DC353FF5AB4C8FEA0 (URL)
Dataset: http://table.plazi.org/id/42C2B0ADD56AA722C353FF5AB5EBFEA0 (URL)

References

  • 1. Achtman AH, Pilat S, Law CW, Lynn DJ, Janot L, Mayer ML, Ma S, Kindrachuk J, Finlay BB, Brinkman FS, Symth GK, Hancock RE, Schofield L. 2012. Effective adjunctive therapy by an innate defense regulatory peptide in a preclinical model of severe malaria. Science Translational Medicine, 4, 135ra64.
  • 2. Agnandji ST, Lell B, Fernandes JF, Abossolo BP, Methogo BG, Kabwende AL, Adegnika AA, Kabwende AL, Mordmuller B, Issifou S, Kremsner PG, Sacarlal J, Aide P, Lanaspa M, Aponte JJ, Machevo S, Acacio S, Bulo H, Sigauque B, Macete E, Alonso P, Abdulla S, Salim N, Minja R, Mpina M, Ahmed S, Ali AM, Mtoro AT, Hamad AS, Mutani P, Tanner M, Tinto H, D'Alessandro U, Sorgho H, Valea I, Bihoun B, Guiraud I, Kabore B, Sombie O, Guiguemde RT, Ouedraogo JB, Hamel MJ, Kariuki S, Oneko M, Odero C, Otieno K, Awino N, McMorrow M, Muturi-Kioi V, Laserson KF, Slutsker L, Otieno W, Otieno L, Otsyula N, Gondi S, Otieno A, Owira V, Oguk E, Odongo G, Woods JB, Ogutu B, Njuguna P, Chilengi R, Akoo P, Kerubo C, Maingi C, Lang T, Olotu A, Bejon P, Marsh K, Mwambingu G, Owusu-Agyei S, Asante KP, Osei-Kwakye K, Boahen O, Dosoo D, Asante I, Adjei G, Kwara E, Chandramohan D, Greenwood B, Lusingu J, Gesase S, Malabeja A, Abdul O, Mahende C, Liheluka E, Malle L, Lemnge M, Theander TG, Drakeley C, Ansong D, Agbenyega T, Adjei S, Boateng HO, Rettig T, Bawa J, Sylverken J, Sambian D, Sarfo A, Agyekum A, Martinson F, Hoffman I, Mvalo T, Kamthunzi P, Nkomo R, Tembo T, Tegha G, Tsidya M, Kilembe J, Chawinga C, Ballou WR, Cohen J, Guerra Y, Jongert E, Lapierre D, Leach A, Lievens M, Ofori-Anyinam O, Olivier A, Vekemans J, Carter T, Kaslow D, Leboulleux D, Loucq C, Radford A, Savarese B, Schellenberg D, Sillman M, Vansadia P. 2012. A phase 3 trial of RTS, S/AS01 malaria vaccine in African infants. New England Journal of Medicine, 367, 2284-2295.
  • 3. Aide P, Aponte JJ, Renom M, Nhampossa T, Sacarlal J, Mandomando I, Bassat Q, Manaca MN, Leach A, Lievens M, Vekemans J, Dubois MC, Loucq C, Ballou WR, Cohen J, Alonso PL. 2010. Safety, immunogenicity and duration of protection of the RTS, S/AS02(D) malaria vaccine: one year follow-up of a randomized controlled phase I/IIb trial. PLoS One, 5, e13838.
  • 4. Alving CR. 2002. Design and selection of vaccine adjuvants: animal models and human trials. Vaccine, 20, S56-S64.
  • 5. Antia M, Herricks T, Rathod PK. 2007. Microfluidic modeling of cell-cell interactions in malaria pathogenesis. PLoS Pathogen, 3, 99.
  • 6. Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois AC, Khim N, Kim S, Duru V, Bouchier C, Ma L, Lim P, Leang R, Duong S, Sreng S, Suon S, Chuor CM, Bout DM, Menard S, Rogers WO, Genton B, Fandeur T, Miotto O, Ringwald P, Le Bras J, Berry A, Barale JC, Fairhurst RM, Benoit-Vical F, Mercereau-Puijalon O, Menard D. 2014. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature, 505, 50-55.
  • 7. Asami M, Owhashi M, Abe T, Nawa Y. 1991. Susceptibility of multipotent haemopoietic stem cell deficient W/Wv mice to Plasmodium berghei -infection. Immunology and Cell Biology, 69, 355-360.
  • 8. Babiker HA, Hastings IM, Swedberg G. 2009. Impaired fitness of drug-resistant malaria parasites: evidence and implication on drug-deployment policies. Expert Review of Anti-infective Therapy, 7, 581-593.
  • 9. Bacon DJ, Jambou R, Fandeur T, Le Bras J, Wongsrichanalai C, Fukuda MM, Ringwald P, Sibley CH, Kyle DE. 2007. World antimalarial resistance network (WARN)II: in vitro antimalarial drug susceptibility. Malaria Journal, 6, 120.
  • 10. Barnes KI, Lindegardh N, Ogundahunsi O, Olliaro P, Plowe CV, Randrianarivelojosia M, Gbotosho GO, Watkins WM, Sibley CH, White NJ. 2007. World Antimalarial Resistance Network (WARN) IV: clinical pharmacology. Malaria Journal, 6, 122.
  • 11. Barnes KI, Watkins WM, White NJ. 2008. Antimalarial dosing regimens and drug resistance. Trends in Parasitology, 24, 127-134.
  • 12. Barratt G. 2003. Colloidal drug carriers: achievements and perspectives. Cellular and Molecular Life Sciences, 60, 21-37.
  • 13. Baum J, Papenfuss AT, Mair GR, Janse CJ, Vlachou D, Waters AP, Cowman AF, Crabb BS, de Koning-Ward TF. 2009. Molecular genetics and comparative genomics reveal RNAi is not functional in malaria parasites. Nucleic Acids Research, 37, 3788-3798.
  • 14. Belyaev NN, Brown DE, Diaz AI, Rae A, Jarra W, Thompson J, Langhorne J, Potocnik AJ. 2010. Induction of an IL7-R(+)c-Kit(hi) myelolymphoid progenitor critically dependent on IFNgamma signaling during acute malaria. Nature Immunology, 11, 477-485.
  • 15. Bessalle R, Gorea A, Shalit I, Metzger JW, Dass C, Desiderio DM, Fridkin M. 1993. Structure-function study of amphiphilic peptides. Journal of Medicinal Chemistry, 36, 1203-1209.
  • 16. Bjorkman A, Phillips-Howard PA. 1990. The epidemiology of drug-resistant malaria. Transactions of Royal Society Tropical Medicine and Hygiene, 84, 177-180.
  • 17. Blondelle SE, Houghten RA. 1992. Design of model peptides having potent antimicrobial activities. Biochemistry, 31, 12688-12694.
  • 18. Bouchaud O, Imbert P, Touze JE, Dodoo AN, Danis M, Legros F. 2009. Fatal cardiotoxicity related to halofantrine: a review based on a worldwide safety data base. Malaria Journal, 8, 289.
  • 19. Bray PG, Martin RE, Tilley L, Ward SA, Kirk K, Fidock DA. 2005. Defining the role of PfCRT in Plasmodium falciparum chloroquine resistance. Molecular Microbiology, 56, 323-333.
  • 20. Bruce-Chwatt LJ, Black RH, Canfield CJ, Clyde DF, Peters W, Wernsdorfer WH. 1986. Chemotherapy of malaria. Revised 2nd ed., World Health Organization: Geneva.
  • 21. Catteruccia F, Levashina EA. 2009. RNAi in the malaria vector, Anopheles gambiae. Methods in Molecular Biology, 555, 63-75.
  • 22. Charoenvit Y, Brice GT, Bacon D, Majam V, Williams J, Abot E, Ganeshan H, Sedegah M, Doolan DL, Carucci DJ, Zimmerman DH. 2004. A small peptide (CEL-1000) derived from the betachain of the human major histocompatibility complex class II molecule induces complete protection against malaria in an antigen-independent manner. Antimicrobial Agents and Chemotherapy, 48, 2455-2463.
  • 23. Chimanuka B, Gabriels M, Detaevernier MR, Plaizier-Vercammen JA. 2002. Preparation of beta-artemether liposomes, their HPLC-UVevaluation and relevance for clearing recrudescent parasitaemia in Plasmodium chabaudi malaria-infected mice. Journal of Pharmaceutical and Biomedical Analysis, 28, 13-22.
  • 24. Chin CD, Linder V, Sia SK. 2007. Lab-on-a-chip devices for global health: past studies and future opportunities. Lab on a Chip, 7, 41-57.
  • 25. Cowman AF, Baldi DL, Healer J, Mills KE, O'Donnell RA, Reed MB, Triglia T, Wickham ME, Crabb BS. 2000. Functional analysis of proteins involved in Plasmodium falciparum merozoite invasion of red blood cells. FEBS Letters, 476, 84-88.
  • 26. Date AA, Joshi MD, Patravale VB. 2007. Parasitic diseases: liposomes and polymeric nanoparticles versus lipid nanoparticles. Advance Drug Delivery Reviews, 59, 505-521.
  • 27. Darkin-Rattray SJ, Gurnett AM, Myers RW, Dulski PM, Crumley TM, Allocco JJ, Cannova C, Meinke PT, Colletti SL, Bednarek MA, Singh SB, Goetz MA, Dombrowski AW, Polishook JD, Schmatz DM. 1996. Apicidin: a novel antiprotozoal agent that inhibits parasite histone deacetylase. Proceedings of the National Academy of Sciences of the United States of America, 93, 13143-13147.
  • 28. Dittrich PS, Manz A. 2006. Lab-on-a-chip: microfluidics in drug discovery. Nature Reviews Drug Discovery, 5, 210-218.
  • 29. Djimde A, Doumbo OK, Cortese JF, Kayentao K, Doumbo S, Diourte Y, Coulibaly D, Dicko A, Su XZ, Nomura T, Fidock DA, Wellems TE, Plowe CV. 2001. A molecular marker for chloroquine-resistant falciparum malaria. New England Journal of Medicine, 344, 257-263.
  • 30. Dondorp AM, Fairhurst RM, Slutsker L, Macarthur JR, Breman JG, Guerin PJ, Wellems TE, Ringwald P, Newman RD, Plowe CV. 2011. The threat of artemisinin-resistant malaria. New England Journal of Medicine, 365, 1073-1075.
  • 31. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, Lwin KM, Ariey F, Hanpithakpong W, Lee SJ, Ringwald P, Silamut K, Imwong M, Chotivanich K, Lim P, Herdman T, An SS, Yeung S, Singhasivanon P, Day NP, Lindegardh N, Socheat D, White NJ. 2009. Artemisinin resistance in Plasmodium falciparum malaria. New England Journal of Medicine, 361, 455-467.
  • 32. Drinnenberg IA, Weinberg DE, Xie KT, Mower JP, Wolfe KH, Fink GR, Bartel DP. 2009. RNAi in budding yeast. Science, 23, 544-550.
  • 33. Duraisingh MT, Cowman AF. 2005. Contribution of the Pfmdr1 gene to antimalarial drug resistance. Acta Tropica, 94, 181-190.
  • 34. Eijkel JCT, Van den Berg A. 2005. Nanofluidics: what is it and what can we expect from it? Microfluids and Nanofluidics, 1, 249-267.
  • 35. El-Ali J, Sorger PK, Jensen KF. 2006. Cells on chips. Nature, 442, 403-411.
  • 36. Elbadry MA, Existe A, Victor YS, Memnon G, Fukuda M, Dame JB, Yowell CA, Okech BA. 2013. Survey of Plasmodium falciparum multidrug resistance-1 and chloroquine resistance transporter alleles in Haiti. Malaria Journal, 12, 426.
  • 37. Eltayeb SE, Su Z, Shi Y, Li S, Xiao Y, Ping Q. 2013. Preparation and optimization of transferrin-modifiedartemether lipid nanospheres based on the orthogonal design of emulsion formulation and physically electrostatic adsorption. International Journal of Pharmaceutics, 452, 321-332.
  • 38. Enserink M. 2010. Malaria's drug miracle in danger. Science, 328, 844-846.
  • 39. Fennell BJ, Carolan S, Pettit GR, Bell A. 2003. Effects of the antimitotic natural product dolastatin 10, and related peptides, on the human malarial parasite Plasmodium falciparum. Journal of Antimicrobial Chemotherapy, 51, 833-841.
  • 40. Ferdig MT, Cooper RA, Mu J, Deng B, Joy DA, Su XZ, Wellems TE. 2004. Dissecting the loci of low-level quinine resistance in malaria parasites. Molecular Microbiology, 52, 985-997.
  • 41. Fire A. 1999. RNA-triggered gene silencing. Trends in Genetics, 15, 358-363.
  • 42. Foote SJ, Cowman AF. 1994. The mode of action and the mechanism of resistance to antimalarial drugs. Acta Tropica, 56, 157-171.
  • 43. Forrest ML, Kwon GS. 2008. Clinical developments in drug delivery nanotechnology. Advance Drug Delivery Reviews, 60, 861-862.
  • 44. Gissot M, Briquet S, Refour P, Boschet C, Vaquero C. 2005. PfMyb1, a Plasmodium falciparum transcription factor, is required for intra-erythrocytic growth and controls key genes for cell cycle regulation. Journal of Molecular Biology, 346, 29-42.
  • 45. Global report on Antimalarial Drug efficacy and Drug Resistance: World Health Organization. 2000-2010.
  • 46. Gosh JK, Shaool D, Guillaud P, Ciceron L, Mazier D, Kustanovich I, Shai Y, Mor A. 1997. Selective cytotoxicity of dermaseptin S3 toward intraerythrocytic Plasmodium falciparum and the underlying molecular basis. Journal of Biological Chemistry, 272, 31609-31616.
  • 47. Goodman CD, McFadden GI. 2013. Targeting apicoplasts in malaria parasites. Expert Opinion on Therapeutic Targets, 17, 167-170.
  • 48. Gref R, Domb A, Quellec P, Blunk T, Muller RH, Verbavatz JM, Langer R. 2012. The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres. Advance Drug Delivery Reviews, 64, 316-326.
  • 49. Gregson A, Plowe CV. 2005. Mechanisms of resistance of malaria parasites to antifolates. Pharmacological Reviews, 57, 117-145.
  • 50. Gupta Y, Jain A, Jain SK. 2007. Transferrin-conjugated solid lipid nanoparticles for enhanced delivery of quinine dihydrochloride to the brain. Journal of Pharmacy and Pharmacology, 59, 935-940.
  • 51. Hastings I, Watkins WM, White NJ. 2002. Pharmacokinetic parameters affecting the evolution of drug-resistance in malaria: the role of the terminal elimination half-life. Philosophical Transactions of the Royal Society B: Biological Science, 357, 505-519.
  • 52. Hastings IM. 2006. Complex dynamics and stability of resistance to antimalarial drugs. Parasitology, 132, 615-624.
  • 53. Henry M, Briolant S, Zettor A, Pelleau S, Baragatti M, Baret E, Mosnier J, Amalvict R, Fusai T, Rogier C, Pradines B. 2009. Plasmodium falciparum Na+/H+ exchanger 1 transporter is involved in reduced susceptibility to quinine. Antimicrobial Agents and Chemotherapy, 53, 1926-1930.
  • 54. Hyde JE. 2002. Mechanisms of resistance of Plasmodium falciparum to antimalarial drugs. Microbes and Infection, 4, 165-174.
  • 55. Imwong M, Dondorp AM, Nosten F, Yi P, Mungthin M, Hanchana S, Das D, Phyo AP, Lwin KM, Pukrittayakamee S, Lee SJ, Saisung S, Koecharoen K, Nguon C, Day NP, Socheat D, White NJ. 2010. Exploring the contribution of candidate genes to artemisinin resistance in Plasmodium falciparum. Antimicrobial Agents and Chemotherapy, 54, 2886-2892.
  • 56. Isacchi B, Arrigucci S, La Marca G, Bergonzi MC, Vannucchi MG, Novelli A, Bilia AR. 2011. Conventional and long-circulating liposomes of artemisinin: preparation, characterization, and pharmacokinetic profile in mice. Journal of Liposome Research, 21, 237-244.
  • 57. Jain K, Sood S, Gowthamarajan K. 2014. Lipid nanocarriers and molecular targets for malaria chemotherapy. Current Drug Targets, 15, 292-312.
  • 58. Kang L, Chung BG, Langer R, Khademhosseini A. 2008. Microfluidics for drug discovery and development: from target selection to product lifecycle management. Drug Discovery, 13, 1-13.
  • 59. Kayser O, Kiderlen AF. 2003. Delivery strategies for antiparasitics. Expert Opinion on Investigational Drugs, 12, 197-207.
  • 60. Korsinczky M, Chen N, Kotecka B, Saul A, Rieckmann K, Cheng Q. 2000. Mutations in Plasmodium falciparum cytochrome b that are associated with atovaquone resistance are located at a putative drug-binding site. Antimicrobial Agents and Chemotherapy, 44, 2100-2108.
  • 61. Krishna S, Pulcini S, Moore CM, Teo B, Staines HM. 2014. Pumped up: reflections on PfATP6 as the target for artemisinins. Trends in Pharmacological Sciences, 35, 4-11.
  • 62. Krugliak M, Feder R, Zolotarev VY. 2000. Antimalarial activities of Dermaseptin S4 derivatives. Antimicrobial Agents and Chemotherapy, 44, 2442-2451.
  • 63. Kumar R, Adams B, Oldenburg A, Musiyenko A, Barik S. 2002. Characterisation and expression of a PP1 serine/ threonine protein phosphatase (PfPP1) from the malaria parasite, Plasmodium falciparum: demonstration of its essential role using RNA interference. Malaria Journal, 1, 5.
  • 64. Lagally ET, Scherer JR, Blazej RG, Toriello NM, Diep BA, Ramchandani M, Sensabaugh GF, Riley LW, Mathies RA. 2004. Integrated portable genetic analysis microsystem for pathogen/infectious disease detection. Analytical Chemistry, 76, 3162-3170.
  • 65. Lasic DD, Martin FJ, Mayhew E. 1991. Stealth liposomes. Annals of Biomedical Engineering, 91, 594.
  • 66. Legrand P, Mosqueira V, Loiseau P, Bories C, Barratt G. 2003. Long circulating nanocapsules: interest in the treatment of severe malaria with halofantrine. Annales Pharmaceutiques Francaises, 61, 196-202.
  • 67. Lewis IA, Wacker M, Olszewski KL, Cobbold SA, Baska KS, Tan A, Ferdig MT, Llinas M. 2014. Metabolic QTL analysis links chloroquine resistance in Plasmodium falciparum to impaired hemoglobin catabolism. PLoS Genetics, 10, 1004085.
  • 68. Linington RG, Gonzalez J, Urena LD, Romero LI, Ortega-Barria E, Gerwick WH. 2007. Venturamides A and B: antimalarial constituents of the panamanian marine cyanobacterium Oscillatoria sp. Journal of Natural Products, 70, 397-400.
  • 69. Londono BL, Eisele TP, Keating J, Bennett A, Chattopadhyay C, Heyliger G, Mack B, Rawson I, Vely JF, Desinor O, Krogstad DJ. 2009. Chloroquine-resistant haplotype Plasmodium falciparum parasites, Haiti. Emerging Infectious Diseases, 15, 735-740.
  • 70. Looareesuwan S, Viravan C, Webster HK, Kyle DE, Hutchinson DB, Canfield CJ. 1996. Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand. American Journal of Tropical Medicine and Hygiene, 54, 62-66.
  • 71. MacRae JI, Marechal E, Biot C, Botte CY. 2012. The apicoplast: a key target to cure malaria. Current Pharmaceutical Design, 18, 3490-3504.
  • 72. Malhotra P, Dasaradhi PV, Kumar A, Mohmmed A, Agrawal N, Bhatnagar RK, Chauhan VS. 2002. Double-stranded RNAmediated gene silencing of cysteine proteases (falcipain-1 and -2) of Plasmodium falciparum. Molecular Microbiology, 45, 1245-1254.
  • 73. Maude RJ, Pontavornpinyo W, Saralamba S, Aguas R, Yeung S, Dondorp AM, Day NP, White NJ, White LJ. 2009. The last man standing is the most resistant: eliminating artemisinin-resistant malaria in Cambodia. Malaria Journal, 8, 31.
  • 74. McRobert L, McConkey GA. 2002. RNA interference (RNAi) inhibits growth of Plasmodium falciparum. Molecular and Biochemical Parasitology, 119, 273-278.
  • 75. Miotto O, Almagro-Garcia J, Manske M, Macinnis B, Campino S, Rockett KA, Amaratunga C, Lim P, Suon S, Sreng S, Anderson JM, Duong S, Nguon C, Chuor CM, Saunders D, Se Y, Lon C, Fukuda MM, Amenga-Etego L, Hodgson AV, Asoala V, Imwong M, Takala-Harrison S, Nosten F, Su XZ, Ringwald P, Ariey F, Dolecek C, Hien TT, Boni MF, Thai CQ, Amambua-Ngwa A, Conway DJ, Djimde AA, Doumbo OK, Zongo I, Ouedraogo JB, Alcock D, Drury E, Auburn S, Koch O, Sanders M, Hubbart C, Maslen G, Ruano-Rubio V, Jyothi D, Miles A, O'Brien J, Gamble C, Oyola SO, Rayner JC, Newbold CI, Berriman M, Spencer CC, McVean G, Day NP, White NJ, Bethell D, Dondorp AM, Plowe CV, Fairhurst RM, Kwiatkowski DP. 2013. Multiple populations of artemisinin-resistant Plasmodium falciparum in Cambodia. Nature Genetics, 45, 648-655.
  • 76. Mizuno Y, Makioka A, Kawazu S, Kano S, Kawai S, Akaki M, Aikawa M, Ohtomo H. 2002. Effect of jasplakinolide on the growth, invasion, and actin cytoskeleton of Plasmodium falciparum. Parasitology Research, 88, 844-848.
  • 77. Mohmmed A, Dasaradhi PV, Bhatnagar RK, Chauhan VS, Malhotra P. 2003. In vivo gene silencing in Plasmodium berghei - a mouse malaria model. Biochemical and Biophysical Research Communications, 309, 506-511.
  • 78. Mosqueira VC, Loiseau PM, Bories C, Legrand P, Devissaguet JP, Barratt G. 2004. Efficacy and pharmacokinetics of intravenous nanocapsule formulations of halofantrine in Plasmodium berghei -infected mice. Antimicrobial Agents of Chemotherapy, 48, 1222-1228.
  • 79. Movellan J, Urban P, Moles E, de la Fuente JM, Sierra T, Serrano JL, Fernandez-Busquets X. 2014. Amphiphilic dendritic derivatives as nanocarriers for the targeted delivery of antimalarial drugs. Biomaterials, 35, 7940-7950.
  • 80. Mueller AK, Hammerschmidt-Kamper C, Kaiser A. 2014. RNAi in Plasmodium. Current Pharmaceutical Design, 20, 278-283.
  • 81. Myers FB, Lee LP. 2008. Innovations in optical microfluidic technologies for point-of-care diagnostics. Lab on a Chip, 8, 2015-2031.
  • 82. Nagaraj G, Uma MV, Shivayogi MS, Balaram H. 2001. Antibiotics isolated from fungi antimalarial activities of peptide. Antimicrobial Agents and Chemotherapy, 45, 145.
  • 83. Newton PN, Ward S, Angus BJ. 2006. Early treatment failure in severe malaria resulting from abnormally low plasma quinine concentrations. Transactions of the Royal Society of Tropical Medicine and Hygiene, 100, 184-186.
  • 84. Nilanonta C, Isaka M, Kittakoop P, Palittapongarnpim P, Kamchonwongpaisan S, Pittayakhajonwut D, Tanticharoen M, et al. 2000. Antimycobacterial and antiplasmodial Cyclodepsipeptides from the insect pathogenic fungus Paecilomyces tenuipes BCC 1614. Planta Medica, 66, 756-758.
  • 85. Nixon GL, Pidathala C, Shone AE, Antoine T, Fisher N, O'Neill PM, Ward SA, Biagini GA. 2013. Targeting the mitochondrial electron transport chain of Plasmodium falciparum: new strategies towards the development of improved antimalarials for the elimination era. Future Medicinal Chemistry, 5, 1573-1591.
  • 86. Noedl H, Se Y, Schaecher K, Socheat D, Fukuda MM. 2008. Evidence of artemisinin-resistant malaria in western Cambodia. New England Journal of Medicine, 359, 2619-2620.
  • 87. Okombo J, Kiara SM, Rono J, Mwai L, Pole L, Ohuma E, Borrmann S, Ochola LI, Nzila A. 2010. In vitro activities of quinine and other antimalarials and pfnhe polymorphisms in Plasmodium isolates from Kenya. Antimicrobial Agents and Chemotherapy, 54, 3302-3307.
  • 88. Ongsrichanalai C, Sirichaisinthop J, Karwacki JJ, Congpuong K, Miller RS, Pang L, Thimasarn K. 2001. Drug resistant malaria on the Thai-Myanmar and Thai-Cambodian borders. Southeast Asian Journal of Tropical Medicine and Public Health, 32, 41-49.
  • 89. Peek LJ, Middaugh CR, Berkland C. 2008. Nanotechnology in vaccine delivery. Advance Drug Delivery Reviews, 60, 915-928.
  • 90. Bloland PB. 2001. Drug resistance in malaria. World Health Organization: Geneva, WHO/CDS/CSR/DRS/2001.4.
  • 91. Peters W. 1987. Resistance of human malaria I, III and IV, in Chemotherapy and drug resistance in malaria, 2nd ed., Academic Press: London. p. 543-568, 593-658, 659-786.
  • 92. Peters W. 1990. The prevention of antimalarial drug resistance. Pharmacology Therapy, 47, 499-508.
  • 93. Perez-Picaso L, Velasco-Bejarano B, Aguilar-Guadarrama AB, Argotte-Ramos R, Rios MY. 2009. Antimalarial activity of ultra-short peptides. Molecules, 14, 5103-5114.
  • 94. Polpanich D, Tangboriboonrat P, Elaissari A, Udomsangpetch R. 2007. Detection of malaria infection via latex agglutination assay. Analytical Chemistry, 79, 4690-4695.
  • 95. Postma NS, Crommelin DJ, Eling WM, Zuidema J. 1999. Treatment with liposome-bound recombinant human tumor necrosis factor-alpha suppresses parasitemia and protects against Plasmodium berghei k173-induced experimental cerebral malaria in mice. Journal of Pharmacology and Experimental Therapeutics, 288, 114-120.
  • 96. Pushparaj PN, Aarthi JJ, Kumar SD, Manikandan J. 2008. RNAi and RNAa - the Yin and Yang of RNAome. Bioinformation, 2, 235-237.
  • 97. Raabe CA, Sanchez CP, Randau G, Robeck T, Skryabin BV, Chinni SV, Kube M, Reinhardt R, Ng GH, Manickam R, Kuryshev VY, Lanzer M, Brosius J, Tang TH, Rozhdestvensky TS. 2010. A global view of the nonprotein-coding transcriptome in Plasmodium falciparum. Nucleic Acids Research, 38(2), 608-617.
  • 98. Rautenbach M, Vlok NM, Stander M, Hoppe HC. 2007. Inhibition of malaria parasite blood stages by tyrocidines, membrane-active cyclic peptide antibiotics from Bacillus brevis. Biochimica et Biophysica Acta, 1768, 1488-1497.
  • 99. Thakur RS, Sultan T, Sanyal A, Atul PK, Punia P, Das J. 2013. Mesenchymal stem cells play an important role in host protective immune responses against malaria by modulating regulatory T cells. European Journal of Immunology, 43, 2070-2077.
  • 100. Robertson RT, Baratta JL, Haynes SM, Longmuir KJ. 2008. Liposomes incorporating a Plasmodium amino acid sequence target heparan sulfate binding sites in liver. Journal of Pharmaceutical Sciences, 97, 3257-3273.
  • 101. Rojas-Rivero L, Gay F, Bustos MD, Ciceron L, Pichet C, Danis M, Gentilini M. 1992. Mefloquine-halofantrine cross-resistance in Plasmodium falciparum induced by intermittent mefloquine pressure. American Journal of Tropical Medicine and Hygiene, 47, 372-377.
  • 102. Roper C, Pearce R, Nair S, Sharp B, Nosten F, Anderson T. 2004. Intercontinental spread of pyrimethamine-resistant malaria. Science, 305, 1124.
  • 103. Rosenthal PJ, Wollish WS, Palmer JT, Rasnick D. 1991. Antimalarial effects of peptide inhibitors of a Plasmodium falciparum cysteine proteinase. Journal of Clinical Investigation, 88, 1467-1472.
  • 104. Sabareesh V, Ranganayaki RS, Raghothama S, Bopanna MP, Balaram H, Srinivasan MC, Balaram P. 2007. Identification and characterization of a library of microheterogeneous cyclohexadepsipeptides from the fungus Isaria. Journal of Natural Products, 70, 715-729.
  • 105. Saei AA, Ahmadian S. 2009. Stem cell engineering might be protective against severe malaria. Bioscience Hypothesis, 2, 48-49.
  • 106. Sa JM, Twu O, Hayton K, Reyes S, Fay MP, Ringwald P, Wellems TE. 2009. Geographic patterns of Plasmodium falciparum drug resistance distinguished by differential responses to amodiaquine and chloroquine. Proceedings of the National Academy of Sciences of the United States of America, 106, 18883-18889.
  • 107. Santos-Magalhaes NS, Mosqueira VC. 2010. Nanotechnology applied to the treatment of malaria. Advance Drug Delivery Reviews, 62, 560-575.
  • 108. Satimai W, Sudathip P, Vijaykadga S, Khamsiriwatchara A, Sawang S, Potithavoranan T, Sangvicheanet A, Delacollette C, Singhasivanon P, Kaewkungwal J, Lawpoolsri S. 2012. Artemisinin resistance containment project in Thailand. II: Responses to mefloquine-artesunate combination therapy among falciparum malaria patients in provinces bordering Cambodia. Malaria Journal, 11, 300.
  • 109. Schwentke A, Krepstakies M, Muller AK, Hammerschmidt-Kamper C, Motaal BA, Bernhard T, Hauber J, Kaiser A. 2012. In vitro and in vivo silencing of plasmodial dhs and eIF-5A genes in a putative, noncanonical RNAi-related pathway. BMC Microbiology, 12, 107.
  • 110. Sharma MK, Rao VK, Agarwal GS, Rai GP, Gopalan N, Prakash S, Sharma SK, Vijayaraghavan R. 2008. Highly sensitive amperometric immunosensor for detection of Plasmodium falciparum histidine-rich protein 2 in serum of humans with malaria: comparison with a commercial kit. Journal of Clinical Microbiology, 46, 3759-3765.
  • 111. Song YS, Moon S, Hulli L, Hasan SK, Kayaalp E, Demirci U. 2009. Microfluidics for cryopreservation. Lab on a Chip, 9, 1874-1881.
  • 112. Stanisic DI, Barry AE, Good MF. 2013. Escaping the immune system: how the malaria parasite makes vaccine development a challenge. Trends in Parasitology, 29, 612-622.
  • 113. Takala-Harrison S, Jacob CG, Arze C, Cummings MP, Silva JC, Dondorp AM, Fukuda MM, Hien TT, Mayxay M, Noedl H, Nosten F, Kyaw MP, Nhien NT, Imwong M, Bethell D, Se Y, Lon C, Tyner SD, Saunders DL, Ariey F, Mercereau-Puijalon O, Menard D, Newton PN, Khanthavong M, Hongvanthong B, Starzengruber P, Fuehrer HP, Swoboda P, Khan WA, Phyo AP, Nyunt MM, Nyunt MH, Brown TS, Adams M, Pepin CS, Bailey J, Tan JC, Ferdig MT, Clark TG, Miotto O, MacInnis B, Kwiatkowski DP, White NJ, Ringwald P, Plowe CV. 2014. Independent emergence of Plasmodium falciparum artemisinin resistance mutations in Southeast Asia. Journal of Infectious Diseases [Epub ahead of print].
  • 114. Tarique M, Tabassum F, Ahmad M, Tuteja R. 2014. Plasmodium falciparum UvrD activities are downregulated by DNA-interacting compounds and its dsRNA inhibits malaria parasite growth. BMC Biochemistry, 15, 9.
  • 115. Tayade NG, Nagarsenker MS. 2010. Development and evaluation of artemether parenteral microemulsion. Indian Journal of Pharmaceutical Sciences, 72, 637-640.
  • 116. Thongtan J, Saenboonrueng J, Rachtawee P, Isaka M. 2006. An antimalarial tetrapeptide from the entomopathogenic fungus Hirsutella sp. BCC 1528. Journal of Natural Products, 69, 713-714.
  • 117. Torrentino-Madamet M, Desplans J, Travaille C, James Y, Parzy D. 2010. Microaerophilic respiratory metabolism of Plasmodium falciparum mitochondrion as a drug target. Current Molecular Medicine, 10, 29-46.
  • 118. Tuteja R, Pradhan A, Sharma S. 2008. Plasmodium falciparum signal peptidase is regulated by phosphorylation and required for intra-erythrocytic growth. Molecular and Biochemical Parasitology, 157, 137-147.
  • 119. Tuteja R, Pradhan A. 2010. Using RNA interference assay we show that PfeIF4A and PfeIF4A (PfH45) are essentially required for the growth and survival of the parasite. PfeIF4E and PfeIF4A colocalize and their double-stranded RNA inhibits Plasmodium falciparum proliferation. Communicative & Integrative Biology, 3, 611-613.
  • 120. Ullu E, Tschudi C, Chakraborty T. 2004. RNA interference in protozoan parasites. Cell Microbiology, 6, 509-519.
  • 121. Urban P, Estelrich J, Cortes A, Fernandez-Busquets X. 2011. A nanovector with complete discrimination for targeted delivery to Plasmodium falciparum -infected versus noninfected red blood cells in vitro. Journal of Control Release, 151, 202-211.
  • 122. Urban P, Valle-Delgado JJ, Mauro N, Marques J, Manfredi A, Rottmann M, et al. 2014. Use of poly(amidoamine) drug conjugates for the delivery of antimalarials to Plasmodium. Journal of Control Release, 177, 84-95.
  • 123. Van Tyne D, Park DJ, Schaffner SF, Neafsey DE, Angelino E, Cortese JF, Barnes KG, Rosen DM, Lukens AK, Daniels RF, Milner DA Jr, Johnson CA, Shlyakhter I, Grossman SR, Becker JS, Yamins D, Karlsson EK, Ndiaye D, Sarr O, Mboup S, Happi C, Furlotte NA, Eskin E, Kang HM, Hartl DL, Birren BW, Wiegand RC, Lander ES, Wirth DF, Volkman SK, Sabeti PC. 2011. Identification and functional validation of the novel antimalarial resistance locus PF10_0355 in Plasmodium falciparum. PLoS Genetics, 7, e1001383.
  • 124. Vial H, Taramelli D, Boulton IC, Ward SA, Doerig C, Chibale K. 2013. CRIMALDDI: platform technologies and novel antimalarial drug targets. Malaria Journal, 12, 396.
  • 125. Ward SA, Bray PG, Mungthin M, Hawley SR. 1995. Current views on the mechanisms of resistance to quinolinecontaining drugs in Plasmodium falciparum. Annals of Tropical Medicine and Parasitology, 89, 121-124.
  • 126. Watkins WM, Mosobo M. 1993. Treatment of Plasmodium falciparum malaria with pyrimethamine-sulphadoxine: selective pressure for resistance is a function of long elimination half-life. Transactions of the Royal Society of Tropical Medicine and Hygiene, 87, 75-78.
  • 127. Watkins WM, Mberu EK, Winstanley PA, Plowe CV. 1999. More on the efficacy of antifolate antimalarial combinations in Africa. Parasitology Today, 15, 131-132.
  • 128. Wernsdorfer WH, Payne D. 1991. The dynamics of drug resistance in Plasmodium falciparum. Pharmacology Therapy, 50, 95-121.
  • 129. Wernsdorfer WH. 1994. Epidemiology of drug resistance in malaria. Acta Tropica, 56, 143-156.
  • 130. West J, Becker M, Tombrink S, Tombrink S, Manz A. 2008. Micro total analysis systems: latest achievements. Analytical Chemistry, 80, 4403-4419.
  • 131. White NJ. 1999. Antimalarial drug resistance and combination chemotherapy. Philosophical Transactions of the Royal Society B: Biological Science, 354, 739-749.
  • 132. WHO. 2001. Antimalarial drug combination therapy. World Health Organization: Geneva.
  • 133. WHO. 2006. WHO calls for an immediate halt to provision of single-drug artemisinin malaria pills. New malaria treatment guidelines issued by WHO. Saudi Medical Journal, 27, 574-575.
  • 134. WHO. 2012. World malaria report 2012. World Health Organization: Geneva.
  • 135. Wichmann O, Muehlberger N, Jelinek T, Alifrangis M, Peyerl-Hoffmann G, Muhlen M, Grobusch MP, Gascon J, Matteelli A, Laferl H, Bisoffi Z, Ehrhardt S, Cuadros J, Hatz C, Gjorup I, McWhinney P, Beran J, da Cunha S, Schulze M, Kollaritsch H, Kern P, Fry G, Richter J. 2000. Screening for mutations related to atovaquone/proguanil resistance in treatment failures and other imported isolates of Plasmodium falciparum in Europe. Journal of Infectious Diseases, 190, 1541-1546.
  • 136. Wiwanitkit V. 2009. Alternative tools for field analysis on malarial infection: a reappraisal. Clinical Therapeutics, 160, 83-85.
  • 137. WHO. 1967. World Malaria Report. World Health Organization: Geneva.
  • 138. WHO. 2010. World Malaria Report. World Health Organization: Geneva.
  • 139. WHO. 2013. World Malaria Report. World Health Organization: Geneva.
  • 140. Yeung S, Pongtavornpinyo W, Hastings IM, Mills AJ, White NJ. 2004. Antimalarial drug resistance, artemisinin-based combination therapy, and the contribution of modeling to elucidating policy choices. American Journal of Tropical Medicine and Hygiene, 71, 179-186.
  • 141. Zhang C, Xiao B, Jiang Y, Zhao Y, Li Z, Gao H, Ling Y, Wei J, Li S, Lu M, Su XZ, Cui H, Yuan J. 2014. Efficient editing of malaria parasite genome using the CRISPR/Cas9 system. Molecular Biology, 5, e01414-14.
  • 142. Zhang Y, Mi JY, Rui YJ, Xu YL, Wang W. 2014. Stem cell therapy for the treatment of parasitic infections: is it far away. Parasitology Research, 113, 607-612.

This site uses cookies. Find out more on how we use cookies